This commentary is written in response to Pezzini's research group commentary, which claimed Liqui-Pellet and liquisolid pellet are not different. Despite some similarities, there are crucial differences separating these two technologies. Liqui-Pellet uses liqui-mass system (wet mass/paste admixture), and liquisolid pellet uses liquisolid system (flowable powder admixture). The understanding of the well-defined term 'liquisolid system' is crucial to understand what is and is not liquisolid formulation. Spireas, who is the inventor of liquisolid technology, clearly defined liquisolid system in his patent document and publications. Since his first publication in 1998, there are around 200 articles about liquisolid formulations (extracted from Scopus), and with no exception, every single one of them followed the original definition of liquisolid system. Liqui-Pellet does not use liquisolid system and so calling it the same as liquisolid pellet, which uses liquisolid system, is incorrect and misleading. The purpose of this commentary is to resolve misunderstanding and support furthering knowledge.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7075839 | PMC |
| http://dx.doi.org/10.1208/s12249-020-01650-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Data-driven insights into the properties of liquisolid systems based on machine learning algorithms.
Eur J Pharm Sci
December 2024
Department of Pharmaceutical Technology and Cosmetology, University of Belgrade - Faculty of Pharmacy, Vojvode Stepe 450, 11221 Belgrade, Serbia.
Article Synopsis
- Liquisolid systems (LS) convert liquid drugs into powder forms, improving their flow, compactness, and bioavailability, prompting increased research efforts to evaluate these systems effectively.
- A comprehensive dataset of 425 formulations was created from literature to analyze factors affecting LS performance, focusing on preparation methods, parameters, and characteristics.
- Machine learning algorithms, like Gradient Boosting and Random Forest, demonstrated over 80% accuracy in predicting key qualities of LS, highlighting their potential as tools for optimizing formulations.
Liquisolid Technique for Solubility Enhancement of Poorly Soluble Drug - A Brief Review.
Curr Drug Discov Technol
October 2024
Department of Pharmaceutics, Brainware University, Kolkata. West Bengal, 700125, India.
Most of the newly discovered drug candidates are lipophilic and poorly water-soluble, making it a significant challenge for the pharmaceutical industry to formulate suitable drug delivery systems. This review gives insight into an overview of the liquisolid technique (LST) and summarizes the progress of its various applications in drug delivery. This novel technique involves converting liquid drugs or drugs in a liquid state (such as solutions, suspensions, or emulsions) into dry, nonadherent, free-flowing, and readily compressible powder mixtures by blending or spraying a liquid dispersion onto specific powder carriers and coating materials.
View Article and Find Full Text PDFDesign and development of Fujicalin-based axitinib liquisolid compacts for improved dissolution and bioavailability to treat renal cell carcinoma.
Eur J Pharm Biopharm
November 2024
Department of Pharmaceutical Quality Assurance, SWVSM's Tatyasaheb Kore College of Pharmacy, Shivaji University Kolhapur, Warananagar - 416113, Maharashtra, India. Electronic address:
Article Synopsis
- Poor dissolution of axitinib (AXT) limits its oral effectiveness, prompting a study on liquisolid technology to enhance its dissolution rate and bioavailability for treating renal cell carcinoma.
- LS compacts were created using specific materials, and various analyses (P-XRD, DSC, SEM) confirmed the transformation of crystalline AXT to a more soluble form, leading to significant improvements in drug dissolution and bioavailability.
- The optimal LS formulation showed a notable increase in drug release (over 99% vs. 18.05% for traditional tablets) and exhibited enhanced cytotoxic effects against cancer cells, suggesting a promising low-cost treatment option for patients.
Comparison of the liquisolid technique and co-milling for loading of a poorly soluble drug in inorganic porous excipients.
Int J Pharm
January 2024
Department of Pharmaceutical Technology, Faculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic. Electronic address:
Drug loading into mesoporous carriers may help to improve the dissolution of poorly aqueous-soluble drugs. However, both preparation method and carrier properties influence loading efficiency and drug release. Accordingly, this study aimed to compare two preparation methods: formulation into liquisolid systems (LSS) and co-milling for their efficiency in loading the poorly soluble model drug cyclosporine A (CyA) into mesoporous magnesium aluminometasilicate Neusilin® US2 (NEU) or functionalized calcium carbonate (FCC).
View Article and Find Full Text PDFIncorporating valsartan in sesame oil enriched self-nanoemulsifying system-loaded liquisolid tablets to improve its bioavailability.
Int J Pharm
May 2023
Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia. Electronic address:
Valsartan (VST) is a poorly soluble antihypertensive drug characterized by its limited dissolution rate and low bioavailability. This study aims to improve VST solubility and dissolution rate via developing liquisolid tablets (LSTs) containing a self-nanoemulsifying drug delivery system (SNEDDS), which is expected to enhance VST bioavailability. This aim was achieved via two designs of experiment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!